Concomitant use of opioids with benzodiazepine or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death (see WARNINGS and PRECAUTIONS – Drug Interactions ). Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.
TUSSIONEX Pennkinetic Extended-Release Suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.
It is important that TUSSIONEX is measured with an accurate measuring device (see PRECAUTIONS, Information for Patients ) . A dosing spoon is provided with the 4 oz (115 mL) packaged product. One side of the spoon is for a 2.5 mL dose. The other side of the spoon is for a 5 mL dose. Fill to level the side of the spoon for the dose that has been prescribed. Do not overfill. Rinse with water after each use. For pres...
Rx only
Concomitant use of opioids with benzodiazepine or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death (see WARNINGS and PRECAUTIONS – Drug Interactions). Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.
Each 5 mL of TUSSIONEX Pennkinetic Extended-Release Suspension contains hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate and chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate. Hydrocodone is a centrally-acting narcotic antitussive. Chlorpheniramine is an antihistamine. TUSSIONEX Pennkinetic Extended-Release Suspension is for oral use only.
Sulfonated styrene-divinylbenzene copolymer complex with 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one.
Sulfonated styrene-divinylbenzene copolymer complex with 2-[p-chloro-α-[2-(dimethylamino)ethyl]-benzyl]pyridine.
Ascorbic acid, D&C Yellow No. 10, ethylcellulose, FD&C Yellow No. 6, flavor, high fructose corn syrup, methylparaben, polyethylene glycol 3350, polysorbate 80, pregelatinized starch, propylene glycol, propylparaben, purified water, sucrose, vegetable oil, xanthan gum.
Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the cough center. In excessive doses, hydrocodone, like other opium derivatives, will depress respiration. The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Hydrocodone can produce miosis, euphoria, and physical and psychological dependence.
Chlorpheniramine is an antihistamine drug (H1 receptor antagonist) that also possesses anticholinergic and sedative activity. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa.
Hydrocodone release from TUSSIONEX Pennkinetic Extended-Release Suspension is controlled by the Pennkinetic System, an extended-release drug delivery system, which combines an ion-exchange polymer matrix with a diffusion rate-limiting permeable coating. Chlorpheniramine release is prolonged by use of an ion-exchange polymer system.
Following multiple dosing with TUSSIONEX Pennkinetic Extended-Release Suspension, hydrocodone mean (S.D.) peak plasma concentrations of 22.8 (5.9) ng/mL occurred at 3.4 hours. Chlorpheniramine mean (S.D.) peak plasma concentrations of 58.4 (14.7) ng/mL occurred at 6.3 hours following multiple dosing. Peak plasma levels obtained with an immediate-release syrup occurred at approximately 1.5 hours for hydrocodone and 2.8 hours for chlorpheniramine. The plasma half-lives of hydrocodone and chlorpheniramine have been reported to be approximately 4 and 16 hours, respectively.
TUSSIONEX Pennkinetic Extended-Release Suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.
TUSSIONEX Pennkinetic Extended-Release Suspension is contraindicated in patients with a known allergy or sensitivity to hydrocodone or chlorpheniramine.
The use of TUSSIONEX Pennkinetic Extended-Release Suspension is contraindicated in children less than 6 years of age due to the risk of fatal respiratory depression.
Concomitant use of opioids, including TUSSIONEX Pennkinetic Extended-Release Suspension, with benzodiazepines, or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Because of these risks, avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol (see PRECAUTIONS – Drug Interactions).
Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol.
Advise both patients and caregivers about the risks of respiratory depression and sedation if TUSSIONEX Pennkinetic Extended-Release Suspension is used with benzodiazepines, alcohol, or other CNS depressants (see PRECAUTIONS – Information for Patients).
As with all narcotics, TUSSIONEX Pennkinetic Extended-Release Suspension produces dose-related respiratory depression by directly acting on brain stem respiratory centers. Hydrocodone affects the center that controls respiratory rhythm and may produce irregular and periodic breathing. Caution should be exercised when TUSSIONEX Pennkinetic Extended-Release Suspension is used postoperatively and in patients with pulmonary disease, or whenever ventilatory function is depressed. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated (see OVERDOSAGE).
The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions, which may obscure the clinical course of patients with head injuries.
The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
Chronic use of narcotics may result in obstructive bowel disease especially in patients with underlying intestinal motility disorder.
The use of TUSSIONEX Pennkinetic Extended-Release Suspension is contraindicated in children less than 6 years of age (see CONTRAINDICATIONS).
In pediatric patients, as well as adults, the respiratory center is sensitive to the depressant action of narcotic cough suppressants in a dose-dependent manner. Caution should be exercised when administering TUSSIONEX Pennkinetic Extended-Release Suspension to pediatric patients 6 years of age and older. Overdose or concomitant administration of TUSSIONEX Pennkinetic Extended-Release Suspension with other respiratory depressants may increase the risk of respiratory depression in pediatric patients. Benefit to risk ratio should be carefully considered, especially in pediatric patients with respiratory embarrassment (e.g., croup) (see PRECAUTIONS).
Caution is advised when prescribing this drug to patients with narrow-angle glaucoma, asthma, or prostatic hypertrophy.
As with any narcotic agent, TUSSIONEX Pennkinetic Extended-Release Suspension should be used with caution in elderly or debilitated patients and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy, or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Inform patients and caregivers that potentially fatal additive effects may occur if TUSSIONEX Pennkinetic Extended-Release Suspension is used with benzodiazepines or other CNS depressants, including alcohol. Because of this risk, patients should avoid concomitant use of TUSSIONEX Pennkinetic Extended-Release Suspension with benzodiazepines or other CNS depressants, including alcohol (see WARNINGS and PRECAUTIONS – Drug Interactions).
Advise patients that TUSSIONEX Pennkinetic Extended-Release Suspension may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid driving or operating machinery during treatment with TUSSIONEX Pennkinetic Extended-Release Suspension.
Advise patients not to dilute TUSSIONEX Pennkinetic Extended-Release Suspension with other fluids and not to mix with other drugs as this may alter the resin-binding and change the absorption rate, possibly increasing the toxicity.
Advise patients that TUSSIONEX Pennkinetic Extended-Release Suspension should be measured with an accurate measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A dosing spoon is provided with the 4 oz (115 mL) packaged product. One side of the spoon is for a 2.5 mL dose. The other side of the spoon is for a 5 mL dose. Instruct the patient to fill to level the side of the spoon for the dose that has been prescribed. The spoon should not be overfilled. Rinse the measuring device or dosing spoon after each use.
Alternatively, a pharmacist can recommend an appropriate measuring device and can provide instructions for measuring the correct dose.
Hydrocodone suppresses the cough reflex; as with all narcotics, caution should be exercised when TUSSIONEX Pennkinetic Extended-Release Suspension is used postoperatively, and in patients with pulmonary disease.
The use of benzodiazepines, opioids, antihistamines, antipsychotics, anti-anxiety agents, or other CNS depressants (including alcohol) concomitantly with TUSSIONEX Pennkinetic Extended-Release Suspension may cause an additive CNS depressant effect, profound sedation, respiratory depression, coma, and death and should be avoided (see WARNINGS).
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
The concurrent use of other anticholinergics with hydrocodone may produce paralytic ileus.
Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with TUSSIONEX Pennkinetic Extended-Release Suspension.
Hydrocodone has been shown to be teratogenic in hamsters when given in doses 700 times the human dose. There are no adequate and well-controlled studies in pregnant women. TUSSIONEX Pennkinetic Extended-Release Suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.
As with all narcotics, administration of TUSSIONEX Pennkinetic Extended-Release Suspension to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from TUSSIONEX Pennkinetic Extended-Release Suspension, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The use of TUSSIONEX Pennkinetic Extended-Release Suspension is contraindicated in children less than 6 years of age (see CONTRAINDICATIONS and ADVERSE REACTIONS, Respiratory, Thoracic and Mediastinal Disorders).
TUSSIONEX Pennkinetic Extended-Release Suspension should be used with caution in pediatric patients 6 years of age and older (see WARNINGS, Pediatric Use).
Clinical studies of TUSSIONEX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Nausea and vomiting may occur; they are more frequent in ambulatory than in recumbent patients. Prolonged administration of TUSSIONEX Pennkinetic Extended-Release Suspension may produce constipation.
Death
Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, euphoria, dizziness, psychic dependence, mood changes.
Ureteral spasm, spasm of vesical sphincters, and urinary retention have been reported with opiates.
Dryness of the pharynx, occasional tightness of the chest, and respiratory depression (see CONTRAINDICATIONS).
TUSSIONEX Pennkinetic Extended-Release Suspension may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (see OVERDOSAGE). Use of TUSSIONEX Pennkinetic Extended-Release Suspension in children less than 6 years of age has been associated with fatal respiratory depression. Overdose with TUSSIONEX Pennkinetic Extended-Release Suspension in children 6 years of age and older, in adolescents, and in adults has been associated with fatal respiratory depression.
Rash, pruritus.
TUSSIONEX Pennkinetic Extended-Release Suspension is a Schedule II narcotic. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, TUSSIONEX Pennkinetic Extended-Release Suspension should be prescribed and administered with caution. However, psychic dependence is unlikely to develop when TUSSIONEX Pennkinetic Extended-Release Suspension is used for a short time for the treatment of cough. Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral narcotic use, although some mild degree of physical dependence may develop after a few days of narcotic therapy.
Serious overdosage with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. Although miosis is characteristic of narcotic overdose, mydriasis may occur in terminal narcosis or severe hypoxia. In severe overdosage apnea, circulatory collapse, cardiac arrest and death may occur. The manifestations of chlorpheniramine overdosage may vary from central nervous system depression to stimulation.
Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdosage or unusual sensitivity to narcotics including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Since the duration of action of hydrocodone in this formulation may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.
It is important that TUSSIONEX is measured with an accurate measuring device (see PRECAUTIONS, Information for Patients).
A dosing spoon is provided with the 4 oz (115 mL) packaged product. One side of the spoon is for a 2.5 mL dose. The other side of the spoon is for a 5 mL dose. Fill to level the side of the spoon for the dose that has been prescribed. Do not overfill. Rinse with water after each use.
For prescriptions where a dosing spoon is not provided, a pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. A household teaspoon is not an accurate measuring device and could lead to overdosage.
Each 5 mL of TUSSIONEX Pennkinetic Extended-Release Suspension contains hydrocodone polistirex equivalent to 10 mg hydrocodone bitartrate, and chlorpheniramine polistirex equivalent to 8 mg chlorpheniramine maleate. Shake well before using. Rinse the measuring device with water after each use.
5 mL every 12 hours; do not exceed 10 mL in 24 hours.
2.5 mL every 12 hours; do not exceed 5 mL in 24 hours.
This medicine is contraindicated in children under 6 years of age (see CONTRAINDICATIONS).
TUSSIONEX Pennkinetic (hydrocodone polistirex and chlorpheniramine polistirex) Extended-Release Suspension, equivalent to 10 mg hydrocodone bitartrate and 8 mg chlorpheniramine maleate per 5 mL, is a gold-colored suspension available as:
Contact: Medical Affairs Department
Phone: (866) 822-0068
Fax: (770) 970-8859
Store at 20 to 25°C (68 to 77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].
TUSSIONEX Pennkinetic Extended-Release Suspension
Manufactured for:
UCB, Inc.
Smyrna, GA 30080
TUSSIONEX and PENNKINETIC are registered trademarks of the UCB Group of companies.
© 2017, UCB, Inc., Smyrna, GA 30080. All rights reserved. Printed in the U.S.A.
Rev. 01/2017
| MEDICATION GUIDE TUSSIONEX® Pennkinetic ® (tuss-i-necks pen-ki-ne-tik) (hydrocodone polistirex and chlorpheniramine polistirex) Extended-Release Suspension CII | |||
|---|---|---|---|
| This Medication Guide has been approved by the U.S. Food and Drug Administration. | Issued: January 2017 | ||
What is the most important information I should know about TUSSIONEX Pennkinetic Extended-Release Suspension?
| |||
|
| ||
| |||
What is TUSSIONEX Pennkinetic Extended-Release Suspension?
| |||
Who should not take TUSSIONEX Pennkinetic Extended-Release Suspension?
| |||
| Before you take TUSSIONEX Pennkinetic Extended-Release Suspension, tell your healthcare provider about all of your medical conditions, including if you: | |||
|
| ||
| |||
| Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. | |||
| Taking TUSSIONEX Pennkinetic Extended-Release Suspension with certain other medicines can cause side effects or affect how well TUSSIONEX Pennkinetic Extended-Release Suspension or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. | |||
Especially tell your healthcare provider if you:
| |||
| Ask your healthcare provider if you are not sure if you take one of these medicines. | |||
How should I take TUSSIONEX Pennkinetic Extended-Release Suspension?
| |||
What should I avoid while taking TUSSIONEX Pennkinetic Extended-Release Suspension?
| |||
| What are the possible side effects of TUSSIONEX Pennkinetic Extended-Release Suspension? | |||
TUSSIONEX Pennkinetic Extended-Release Suspension may cause serious side effects, including:
| |||
The most common side effects of TUSSIONEX Pennkinetic Extended-Release Suspension include:
| |||
| These are not all the possible side effects of TUSSIONEX Pennkinetic Extended-Release Suspension. | |||
| Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |||
How should I store TUSSIONEX Pennkinetic Extended-Release Suspension?
| |||
| General information about the safe and effective use of TUSSIONEX Pennkinetic Extended-Release Suspension. | |||
| Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TUSSIONEX Pennkinetic Extended-Release Suspension for a condition for which it was not prescribed. Do not give TUSSIONEX Pennkinetic Extended-Release Suspension to other people, even if they have the same symptoms that you have. It may harm them. | |||
| You can ask your pharmacist or healthcare provider for information about TUSSIONEX Pennkinetic Extended-Release Suspension that is written for health professionals. | |||
| What are the ingredients in TUSSIONEX Pennkinetic Extended-Release Suspension? | |||
| Active Ingredient: hydrocodone polistirex and chlorpheniramine polistirex | |||
| Inactive Ingredients: Ascorbic acid, D&C Yellow No. 10, ethylcellulose, FD&C Yellow No. 6, flavor, high fructose corn syrup, methylparaben, polyethylene glycol 3350, polysorbate 80, pregelatinized starch, propylene glycol, propylparaben, purified water, sucrose, vegetable oil, xanthan gum. | |||
| Manufactured for: UCB, Inc. Smyrna, GA 30080 For more information about TUSSIONEX Pennkinetic Extended-Release Suspension call 1-844-599-2273. | |||
NDC 53014-548-01
Rx ONLY
CII
Tussionex®
Pennkinetic®
(hydrocodone polistirex and
chlorpheniramine polistirex)
Extended-Release Suspension
equivalent to 10 mg hydrocodone
bitartrate/8 mg chlorpheniramine
maleate per 5 mL
Nonalcoholic
12-hour Dosing
Contraindicated in
children under
6 years of age
Dispense enclosed
Medication Guide to
each patient.
Dispense entire carton
as one unit
4 oz. (115 mL)
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1087459 | HYDROcodone polistirex 10 MG / chlorpheniramine polistirex 8 MG in 5 mL 12HR Extended Release Oral Suspension | PSN | 7 |
| 1087463 | Tussionex Pennkinetic 10 MG / 8 MG in 5 mL 12HR Extended Release Oral Suspension | PSN | 7 |
| 1087463 | 12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Release Suspension [Tussionex] | SBD | 7 |
| 1087459 | 12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Release Suspension | SCD | 7 |
| 1087459 | hydrocodone polistirex 10 MG / chlorpheniramine polistirex 8 MG per 5 ML 12HR Extended Release Oral Suspension | SY | 7 |
| 1087463 | Tussionex Pennkinetic ER (chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML) 12 HR Extended Release Suspension | SY | 7 |
| Class | Version | Type | Effective |
|---|---|---|---|
| CHLORPHENIRAMINE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| HYDROCODONE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 53014-548-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-5518-f424-e053-dadaa90a57ce | Tussionex ® Pennkinetic ® (hydrocodone polistirex and chlorpheniramine polistirex) Extended-Release Suspension CII |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 53014-548-01 | Tussionex Pennkinetic | 1 in 1 CARTON | SUSPENSION, EXTENDED RELEASE | 1 | 7 | |
| 53014-548-01 | Tussionex Pennkinetic | 115 mL in 1 BOTTLE, PLASTIC | SUSPENSION, EXTENDED RELEASE | 115 | 7 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 53014-548 | TUSSIONEX PENNKINETIC (HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX) SUSPENSION, EXTENDED RELEASE [UNITHER MANUFACTURING LLC] | 7 | Legacy NDC, 2 package rows | 20170330_af2caf33-e587-4d80-9523-44e1b565aae2.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 53014-548-01 | ML - Milliliter | 53014-548 | 67b5b137-f879-4cd0-a985-19c0e3bc7a0e | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| chlorpheniramine | ACTIVE INGREDIENT | 3U6IO1965U | 6 | |
| hydrocodone | ACTIVE INGREDIENT | 6YKS4Y3WQ7 | 6 | |
| chlorpheniramine | ACTIVE MOIETY | 3U6IO1965U | 6 | |
| hydrocodone | ACTIVE MOIETY | 6YKS4Y3WQ7 | 6 | |
| ascorbic acid | INACTIVE INGREDIENT | PQ6CK8PD0R | 6 | |
| D&C Yellow No. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 6 | |
| ethylcelluloses | INACTIVE INGREDIENT | 7Z8S9VYZ4B | 6 | |
| FD&C Yellow No. 6 | INACTIVE INGREDIENT | H77VEI93A8 | 6 | |
| high fructose corn syrup | INACTIVE INGREDIENT | XY6UN3QB6S | 6 | |
| methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 6 | |
| polyethylene glycol 3350 | INACTIVE INGREDIENT | G2M7P15E5P | 6 | |
| polysorbate 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 6 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 6 | |
| propylparaben | INACTIVE INGREDIENT | Z8IX2SC1OH | 6 | |
| starch, corn | INACTIVE INGREDIENT | O8232NY3SJ | 6 | |
| sucrose | INACTIVE INGREDIENT | C151H8M554 | 6 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 6 | |
| xanthan gum | INACTIVE INGREDIENT | TTV12P4NEE | 6 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 53014-548 | 53014-548-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| hydrocodone | 6YKS4Y3WQ7 | ACTIR |
| chlorpheniramine | 3U6IO1965U | ACTIR |
| ascorbic acid | PQ6CK8PD0R | IACT |
| D&C Yellow No. 10 | 35SW5USQ3G | IACT |
| ethylcellulose, unspecified | 7Z8S9VYZ4B | IACT |
| FD&C Yellow No. 6 | H77VEI93A8 | IACT |
| high fructose corn syrup | XY6UN3QB6S | IACT |
| methylparaben | A2I8C7HI9T | IACT |
| polyethylene glycol 3350 | G2M7P15E5P | IACT |
| polysorbate 80 | 6OZP39ZG8H | IACT |
| starch, corn | O8232NY3SJ | IACT |
| propylene glycol | 6DC9Q167V3 | IACT |
| propylparaben | Z8IX2SC1OH | IACT |
| water | 059QF0KO0R | IACT |
| sucrose | C151H8M554 | IACT |
| xanthan gum | TTV12P4NEE | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | DROPS / OPHTHALMIC | 0.05 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| sucrose | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SYRUP / ORAL | 81 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SOLUTION / INTRAMUSCULAR | 5 %w/v | ||
| D&C Yellow No. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, COATED / ORAL | 2.5 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | POWDER, FOR SUSPENSION / ORAL | 75 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRAVENOUS | 4680 mg | ||
| polyethylene glycol 3350 | POLYETHYLENE GLYCOL 3350 | G2M7P15E5P | TABLET, EXTENDED RELEASE / ORAL | 61 mg | ||
| D&C Yellow No. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, FILM COATED / ORAL | 120 mg | ||
| D&C Yellow No. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | LOTION / TOPICAL | NA | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | SUSPENSION / RECTAL | 452 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| sucrose | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAMUSCULAR | 6 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | EMULSION / TOPICAL | 34050 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET / ORAL | 56 mg | ||
| sucrose | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SYSTEM / TOPICAL | 42 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION/ DROPS / OPHTHALMIC | 0.25 %w/v | ||
| polyethylene glycol 3350 | POLYETHYLENE GLYCOL 3350 | G2M7P15E5P | SUSPENSION, EXTENDED RELEASE / ORAL | 37 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUPPOSITORY / RECTAL | 72.15 mg | ||
| sucrose | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| sucrose | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| D&C Yellow No. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SOLUTION / RECTAL | NA | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | CONCENTRATE / ORAL | 1 mg/1ml | ||
| starch, corn | STARCH, CORN | O8232NY3SJ | TABLET, DELAYED RELEASE / ORAL | 713 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | DROPS / NASAL | 26 mg | ||
| ethylcelluloses | ETHYLCELLULOSE | 7Z8S9VYZ4B | SUSPENSION, EXTENDED RELEASE / ORAL | NA | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | PASTE, DENTIFRICE / DENTAL | 0.05 %w/w | ||
| ethylcelluloses | ETHYLCELLULOSE | 7Z8S9VYZ4B | CREAM / TOPICAL | NA | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SUBCUTANEOUS | 2 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.3 %w/v | ||
| FD&C Yellow No. 6 | FD&C YELLOW NO. 6 | H77VEI93A8 | SUSPENSION / ORAL | 11 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | ELIXIR / ORAL | 800 mg | ||
| sucrose | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET, ORALLY DISINTEGRATING / ORAL | 0.15 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / RESPIRATORY (INHALATION) | 10 %w/w | ||
| sucrose | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| starch, corn | STARCH, CORN | O8232NY3SJ | TABLET / ORAL | 1116 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | POWDER / ORAL | 275 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET, FILM COATED / ORAL | 0.08 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / VAGINAL | 6.4 %w/w | ||
| ascorbic acid | ASCORBIC ACID | PQ6CK8PD0R | GEL / TOPICAL | 7 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.8 mg | ||
| polyethylene glycol 3350 | POLYETHYLENE GLYCOL 3350 | G2M7P15E5P | CREAM / TOPICAL | 396 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAVENOUS | 6 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | LOZENGE / ORAL | 1264 mg | ||
| ascorbic acid | ASCORBIC ACID | PQ6CK8PD0R | INJECTION / INTRAMUSCULAR | 192 mg | ||
| polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| sucrose | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| ascorbic acid | ASCORBIC ACID | PQ6CK8PD0R | POWDER, FOR SOLUTION / ORAL | 560 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TRANSDERMAL | 500 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N019111-001 | TUSSIONEX PENNKINETIC | CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N019111-001 | TUSSIONEX PENNKINETIC | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SUSPENSION, EXTENDED RELEASE / ORAL | RLD | 1987-12-31 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 0503c2c1-238b-4189-9b9c-08e712fa9313 | af2caf33-e587-4d80-9523-44e1b565aae2 | 2017-01-20 | Boxed warning, Warnings, Adverse reactions | 0503c2c1-238b-4189-9b9c-08e712fa9313 af2caf33-e587-4d80-9523-44e1b565aae2 |
Adverse event summaries are temporarily unavailable. Other product information remains available.